Analyze Diet

Vaccine.

Periodical
Allergy and Immunology
Vaccines
Publisher:
Butterworths,. Amsterdam, The Netherlands : Elsevier Science
Frequency: Thirty-two no. a year, 2001-
Country: Netherlands
Language: English
Start Year:1983 -
ISSN:
0264-410X (Print)
1873-2518 (Electronic)
0264-410X (Linking)
Impact Factor
5.5
2022
NLM ID:8406899
(OCoLC):10399916
(DNLM):V00105000(s)
Coden:VACCDE
LCCN:sn 84006024
Classification:W1 VA239
Prevalence of antibody to Japanese encephalitis virus nonstructural 1 protein among racehorses in Japan: indication of natural infection and need for continuous vaccination.
Vaccine    March 9, 2004   Volume 22, Issue 9-10 1097-1103 doi: 10.1016/j.vaccine.2003.10.001
Konishi E, Shoda M, Kondo T.Japanese encephalitis virus (JEV) causes fatal diseases in equines as well as humans. In Japan, racehorses are vaccinated with inactivated JE vaccine every year and no equine JE cases have been reported since 1986. However, the current reduction in JEV activity in nature has raised an argument against the requirement of continuous vaccination. Here, we studied natural infection rates in racehorses to address the issue. To identify naturally-infected individuals from vaccinated populations, we used an immunostaining method for detecting antibodies to JEV nonstructural 1 (NS1) protein. A total o...
Rabies DNA vaccine in the horse: strategies to improve serological responses.
Vaccine    October 25, 2003   Volume 21, Issue 31 4593-4596 doi: 10.1016/s0264-410x(03)00504-8
Fischer L, Minke J, Dufay N, Baudu P, Audonnet JC.In order for DNA vaccines to become a practical alternative to conventional vaccines their ability to induce antibody responses in large mammals needs to be improved. We used DNA vaccination against rabies in the horse as a model to test the potential of two different strategies to enhance antibody responses in a large mammalian species. The administration of the DNA vaccine in the presence of aluminum phosphate improved both the onset and the intensity of serological responses but was not potent enough to achieve seroconversion in all vaccinated ponies. However, when the DNA vaccine was formu...
Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a DNA vaccine expressing the vapA gene of Rhodococcus equi.
Vaccine    August 19, 2003   Volume 21, Issue 25-26 3815-3825 doi: 10.1016/s0264-410x(03)00329-3
Lopez AM, Hines MT, Palmer GH, Knowles DP, Alperin DC, Hines SA.Rhodococcus equi remains one of the most important pathogens of early life in horses, yet conventional vaccines to prevent rhodococcal pneumonia have not been successful. DNA vaccination offers an alternative to conventional vaccines with specific advantages for immunization of neonates. We developed a DNA vaccine expressing the vapA gene (pVR1055vapA) that induced an anamnestic response characterized by virulence associated protein A (VapA)-specific IgG antibodies in sera and bronchoalveolar lavage fluid (BALF) as well as VapA-specific proliferation of pulmonary lymphocytes when tested in adu...
Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response.
Vaccine    June 12, 2003   Volume 21, Issue 21-22 3081-3092 doi: 10.1016/s0264-410x(03)00161-0
Soboll G, Nelson KM, Leuthner ES, Clark RJ, Drape R, Macklin MD, Swain WF, Olsen CW, Lunn DP.We have previously demonstrated that equine influenza virus hemagglutinin (HA) DNA vaccination protects ponies from challenge infection, and induces protective IgGa and IgGb responses. However, this approach does not induce a nasal IgA response. The objective of this study was to examine the value of cholera toxin (CT) administration as an adjuvant for intranasal HA DNA vaccination, and to measure protection 3 months after DNA vaccination. After an immunogenic dose of CT was determined, ponies were immunized on two occasions by intranasal administration of HA DNA and cholera toxin, or HA DNA a...
An improved Pythium insidiosum-vaccine formulation with enhanced immunotherapeutic properties in horses and dogs with pythiosis.
Vaccine    June 12, 2003   Volume 21, Issue 21-22 2797-2804 doi: 10.1016/s0264-410x(03)00225-1
Mendoza L, Mandy W, Glass R.The immunotherapeutic properties of a new Pythium insidiosum-vaccine formulation (PIV), was evaluated in 18 horses and 6 dogs with proven pythiosis from different enzootic areas in the United States. All injected horses but one responded with a weak (=29 mm, n=3), a mild (30-90 mm, n=7) or a strong (=100 mm, n=7) inflammatory reactions at the site of injection. Three equines with weak or negative reactions at the injection site were not cured. Seven equines with strong reactions at their injection sites, however, were cured. Six of the eight horses with mild reactions were also cured. The rema...
Optimising vaccination strategies in equine influenza.
Vaccine    June 12, 2003   Volume 21, Issue 21-22 2862-2870 doi: 10.1016/s0264-410x(03)00156-7
Park AW, Wood JL, Newton JR, Daly J, Mumford JA, Grenfell BT.A stochastic model of equine influenza (EI) is constructed to assess the risk of an outbreak in a Thoroughbred population at a typical flat race training yard. The model is parameterised using data from equine challenge experiments conducted by the Animal Health Trust (relating to the latent and infectious period of animals) and also published data on previous epidemics (to estimate the transmission rate for equine influenza). Using 89 ponies, an empirical relationship between pre-challenge antibody and the probability of becoming infectious is established using logistic regression. Changes in...
Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge.
Vaccine    January 18, 2003   Volume 21, Issue 5-6 491-506 doi: 10.1016/s0264-410x(02)00474-7
Ridgely SL, Zhang B, McGuire TC.Lipopeptide containing an ELA-A1-restricted cytotoxic T lymphocyte (CTL) epitope from the envelope surface unit (SU) protein of the EIAV(WSU5) strain was used to immunize three horses having the ELA-A1 haplotype. Peptide-specific ELA-A1-restricted CTL were induced in all three horses, although these were present transiently in PBMC. These horses were further immunized with lipopeptide containing the corresponding CTL epitope from the EIAV(PV) strain. Then, the three immunized horses and three non-immunized horses were challenged by intravenous inoculation with 300 TCID(50) EIAV(PV). All horses...
Lipopeptide stimulation of MHC class I-restricted memory cytotoxic T lymphocytes from equine infectious anemia virus-infected horses.
Vaccine    March 22, 2002   Volume 20, Issue 13-14 1809-1819 doi: 10.1016/s0264-410x(01)00517-5
Ridgely SL, McGuire TC.The immunogenicity of equine infectious anemia virus (EIAV) Gag and Env equine leukocyte alloantigen (ELA)-A5.1, -A9, and -A1 restricted cytotoxic T lymphocyte (CTL) epitopes synthesized on multiple antigenic peptide (MAP) system coupled to tripalmitoyl-S-glycerylcysteine (P3C) was evaluated in vitro. P3C-MAP-peptide-stimulated peripheral blood mononuclear cells (PBMCs) from horses, chronically infected with EIAV, had memory CTL (CTLm) similar to that of PBMCs stimulated with either the minimal CTL epitopes, longer peptides containing the CTL epitopes, or EIAV. The stimulated CTL lysed EIAV-in...
Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses.
Vaccine    February 23, 2002   Volume 20, Issue 11-12 1609-1617 doi: 10.1016/s0264-410x(01)00485-6
Balasuriya UB, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, Hedges JF, Williams JC, Johnston RE, David Wilson W, Liu IK, James MacLachlan N.Replicon particles derived from a vaccine strain of Venezuelan equine encephalitis (VEE) virus were used as vectors for expression in vivo of the major envelope proteins (G(L) and M) of equine arteritis virus (EAV), both individually and in heterodimer form (G(L)/M). The immunogenicity of the different replicons was evaluated in horses, as was their ability to protectively immunize horses against intranasal and intrauterine challenge with a virulent strain of EAV (EAV KY84). Horses immunized with replicons that express both the G(L) and M proteins in heterodimer form developed neutralizing ant...
Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin.
Vaccine    February 23, 2002   Volume 20, Issue 11-12 1653-1659 doi: 10.1016/s0264-410x(01)00488-1
Sheoran AS, Artiushin S, Timoney JF.The intranasal immunogenicity of cholera toxin (CT) genetically coupled to peptide sequence aa236-334 (F3) of the SeM protein of Streptococcus equi was studied in five young adult Welsh ponies. All ponies made rapid CTB- and SeMF3-specific serum antibody responses following the first immunization. Specific nasal IgA responses were detected in two ponies 14 days after the first immunization, in another two 14 days after a second immunization on day 14, and in all ponies 28 days after a third immunization on day 42. SeMF3-specific antibody responses in sera and nasal washes were dominated by IgG...
The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant.
Vaccine    January 23, 2002   Volume 20, Issue 7-8 1079-1088 doi: 10.1016/s0264-410x(01)00445-5
Scanlen M, Paweska JT, Verschoor JA, van Dijk AA.We previously demonstrated that soluble baculovirus-expressed African horsesickness virus (AHSV) serotype 5 VP2 protein (AHSV5 rVP2) elicits neutralising antibodies in guinea pigs. We have now determined the immunogenicity of soluble AHSV5 rVP2 in horses when administered in three different adjuvant types, ISA-50, aluminium phosphate and different saponin preparations. Doses of 10 and 50microg of rVP2 administered with saponin induced full protection to a lethal challenge, albeit with dose-related side effects. The results establish that soluble rVP2 is the biologically active form and that it...
Vaccination of foals and pregnant mares with Duvaxyn EHV1, 4 vaccine.
Vaccine    January 23, 2002   Volume 20, Issue 7-8 992 doi: 10.1016/s0264-410x(01)00443-1
Studdert MJ.No abstract available
Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV1,4). Vaccination/challenge experiments in foals and pregnant mares.
Vaccine    July 18, 2001   Volume 19, Issue 30 4307-4317 doi: 10.1016/s0264-410x(01)00131-1
Heldens JG, Hannant D, Cullinane AA, Prendergast MJ, Mumford JA, Nelly M, Kydd JH, Weststrate MW, van den Hoven R.Pregnant mares and young foals were vaccinated with Duvaxyn EHV1,4, an inactivated and adjuvanted vaccine containing both the EHV-1 and 4 antigens. SN and CF antibody titres were induced two weeks after first vaccination. Antibody levels were boosted after second vaccination, however they never reached the levels induced after virus challenge. Young foals were challenged with virulent EHV-1 and EHV-4 field viruses. Pregnant mares were challenged with the highly abortigenic EHV-1 strain Ab4. Vaccinated animals showed a clear reduction in clinical signs and virus excretion compared to unvaccinat...
Intranasal immunogenicity of a Delta cya Delta crp-pabA mutant of Salmonella enterica serotype Typhimurium for the horse.
Vaccine    June 8, 2001   Volume 19, Issue 27 3787-3795 doi: 10.1016/s0264-410x(01)00091-3
Sheoran AS, Timoney JF, Tinge SA, Sundaram P, Curtiss R.The aim of this study was to investigate the intranasal immunogenicity for the horse of a Deltacya Deltacrp-pabA mutant (MGN-707) of Salmonella enterica serotype Typhimurium (S. typhimurium). MGN-707 caused no sign of disease, was not detected in feces and a single administration induced strong Salmonella-specific serum and nasal mucosal antibody responses. All ponies had made strong salmonella specific serum IgGa, IgGb, IgA and IgM antibody responses by day 25 after the first immunization. IgM responses to salmonella lipopolysaccharide (LPS) were short lived whereas salmonella specific serum ...
Intranasal immunogenicity of a Deltacya Deltacrp-pabA mutant of Salmonella enterica serotype Typhimurium for the horse.
Vaccine    May 12, 2001   Volume 19, Issue 25-26 3591-3599 doi: 10.1016/s0264-410x(01)00072-x
Sheoran AS, Timoney JF, Tinge SA, Sundaram P, Curtiss R.The aim of this study was to investigate the intranasal immunogenicity for the horse of a Deltacya Deltacrp-pabA mutant (MGN-707) of Salmonella enterica serotype Typhimurium (S. typhimurium). MGN-707 caused no sign of disease, was not detected in feces and a single administration induced strong Salmonella-specific serum and nasal mucosal antibody responses. All ponies had made strong salmonella specific serum IgGa, IgGb, IgA and IgM antibody responses by day 25 after the first immunization. IgM responses to salmonella lipopolysaccharide (LPS) were short lived whereas salmonella specific serum ...
Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate isobutyrate based delivery system.
Vaccine    October 12, 2000   Volume 19, Issue 4-5 492-497 doi: 10.1016/s0264-410x(00)00187-0
Nally JE, Artiushin S, Sheoran AS, Burns PJ, Simon B, Gilley RM, Gibson J, Sullivan S, Timoney JF.Streptococcus equi causes equine strangles, a highly contagious disease of the upper respiratory tract. The antiphagocytic surface protein SeM is strongly immunogenic and evokes mucosal and systemic antibodies during convalescence. The present study investigated the potential of sucrose acetate isobutyrate (SAIB); a high viscosity excipient that provides controlled release of biologically active substances, to enhance antibody responses following intranasal immunization of horses with a 108 a.a. peptide of SeM (SeMF3). SeMF3-SAIB was administered intranasally to each of the 11 adult horses on ...
Immune responses in mice, cattle and horses to a DNA vaccine for vesicular stomatitis.
Vaccine    March 30, 2000   Volume 18, Issue 22 2368-2374 doi: 10.1016/s0264-410x(00)00007-4
Cantlon JD, Gordy PW, Bowen RA.Vesicular stomatitis (VS) virus causes an important clinical disease of cattle and horses in North America. In order for a vaccine to be useful in the control of VS, it must not only protect against disease, but allow ready differentiation of infected and vaccinated animals. In these studies, we evaluated neutralizing antibody responses in outbred mice, calves, and horses that received a DNA vaccine that expressed the glycoprotein (G) gene of VS New Jersey virus. The vaccine elicited antibody titers in individuals from each species, especially when two doses were administered, but the level of...
Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
Vaccine    October 16, 1999   Volume 18, Issue 5-6 540-548 doi: 10.1016/s0264-410x(99)00187-5
Chang Y, Novosol V, McDonough SP, Chang CF, Jacobson RH, Divers T, Quimby FW, Shin S, Lein DH.Eight 1-year-old ponies were vaccinated with recombinant OspA (ospA gene derived from B. burgdorferi B31) with adjuvant (aluminium hydroxide). Four ponies were used as non-vaccinated controls with adjuvant. One hundred and twelve days after the first vaccination, the vaccinated and non-vaccinated ponies were challenged by exposure to B. burgdorferi-infected adults tick (Ixodes scapularis) collected from Westchester County, New York (tick infection rate >/=60%). Protection from infection was evaluated by culture for B. burgdorferi from three monthly skin biopsies taken near the site of tick bit...
BERNA: a century of immunobiological innovation.
Vaccine    October 3, 1999   Volume 17 Suppl 2 S1-S5 doi: 10.1016/s0264-410x(99)00228-5
Cryz SJ.At the time the Swiss Serum and Vaccine Institute Berne (BERNA) was found in 1898, few vaccines or immune globulins were available. This short list included vaccines against cholera, typhoid fever, plague, smallpox and rabies and equine anti-tetanus and diphtheria immune globulins. Furthermore, their use was restricted due to limited production capacity, uncertainty regarding safety and no public health infrastructure to promote their utilization. Today, safe and effective vaccines exist for more than 30 infectious diseases while human hyperimmune globulins exist to treat or prevent rabies, te...
Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene.
Vaccine    July 14, 1999   Volume 17, Issue 18 2245-2258 doi: 10.1016/s0264-410x(98)00496-4
Lunn DP, Soboll G, Schram BR, Quass J, McGregor MW, Drape RJ, Macklin MD, McCabe DE, Swain WF, Olsen CW.Equine influenza virus infection remains one of the most important infectious diseases of the horse, yet current vaccines offer only limited protection. The equine immune response to natural influenza virus infection results in long-term protective immunity, and is characterized by mucosal IgA and serum IgGa and IgGb antibody responses. DNA vaccination offers a radical alternative to conventional vaccines, with the potential to generate the same protective immune responses seen following viral infection. Antigen-specific antibody isotype responses in serum and mucosal secretions were studied i...
Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination.
Vaccine    July 31, 1998   Volume 16, Issue 13 1306-1313 doi: 10.1016/s0264-410x(98)00009-7
Nelson KM, Schram BR, McGregor MW, Sheoran AS, Olsen CW, Lunn DP.Inactivated alum-adjuvanted conventional equine influenza virus vaccines are of poor efficacy and offer limited short-term protection against infection. In sharp contrast, natural infection with equine influenza virus confers long-term protective immunity. In order to identify the protective immune responses to equine influenza virus, the influenza virus-specific IgA, IgGa, IgGb, IgGc and IgG(T) antibody responses in nasal secretions and serum induced by natural infection and a commercial vaccine were studied by ELISA. Two groups of four influenza-naive ponies were established. In the natural ...
Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia).
Vaccine    October 23, 1997   Volume 15, Issue 14 1523-1528 doi: 10.1016/s0264-410x(97)00098-4
Pratanaphon R, Akesowan S, Khow O, Sriprapat S, Ratanabanangkoon K.Naja kaouthia (NK) causes the highest fatality due to snake venom poisoning in Thailand. The specific antivenom produced is of low potency and in short supply. The aim of this study was to improve the antivenom potency. Bentonite and complete Freund's adjuvants (CFA) and various immunogens were compared. Six groups of three to five horses were immunized as follows: Group 1, NK venom adsorbed on bentonite; Group 2, NK venom in CFA; Group 3, NK venom in CFA in multi-emulsion formulation; Group 4, NK venom in 25% CFA; Group 5, NK neurotoxin 3 (NK3) conjugated with tetanus toxoid (NK3-TT) in CFA; ...
Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice.
Vaccine    July 1, 1997   Volume 15, Issue 10 1149-1156 doi: 10.1016/s0264-410x(96)00309-x
Olsen CW, McGregor MW, Dybdahl-Sissoko N, Schram BR, Nelson KM, Lunn DP, Macklin MD, Swain WF, Hinshaw VS.Two fundamentally different approaches to vaccination of BALB/c mice with the hemagglutinin (HA) of A/Equine/Kentucky/1/81 (H3N8) (Eq/KY) were evaluated, that is, administration of HA protein vs administration of HA-encoding DNA. Each vaccine was tested for its immunogenicity and ability to provide protection from homologous virus challenge. HA protein was synthesized in vitro by infection of Sf21 insect cells with a recombinant baculovirus. Intranasal administration of this vaccine induced virus-specific antibodies, as measured by enzyme-linked immunosorbent assay (ELISA), but did not induce ...
Simulation studies of vaccination strategies in African horse sickness.
Vaccine    April 1, 1997   Volume 15, Issue 5 519-524 doi: 10.1016/s0264-410x(97)00220-x
Lord CC, Woolhouse ME, Mellor PS.A simulation model including two hosts (horses and donkeys) and one vector (Culicoides imicola) for African horse sickness in Spain is extended to consider vaccination strategies. If hosts were protected prior to virus introduction, elimination of simulated epidemics was related nonlinearly to the fraction protected. Protecting donkeys as well as horses increased the effectiveness of vaccination. Prevention of 50% of epidemics required 75% coverage of horses and donkeys or 90% coverage of horses only. Protection after the introduction of the virus was rarely successful in preventing outbreaks....
Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells from healthy horses in Japan.
Vaccine    August 1, 1995   Volume 13, Issue 12 1076-1079 doi: 10.1016/0264-410x(95)00050-b
Nakamura Y, Kishi M, Nakaya T, Asahi S, Tanaka H, Sentsui H, Ikeda K, Ikuta K.Borna disease (BD) is a progressive poliomeningoencephalomyelitis which occurs naturally in horses and sheep. Here, peripheral blood mononuclear cells (PBMC) derived from 57 healthy horses in Japan were examined by a nested reverse transcription-polymerase chain reaction to determine the prevalence of BD virus (BDV) infection. Seventeen (29.8%) of the samples were positive by this examination and the specificity of the amplified product was confirmed by hybridization with authentic oligomer probes. About 60% of the BDV RNA-positive individuals also showed seropositivity by Western blotting. Th...
Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses.
Vaccine    February 1, 1995   Volume 13, Issue 3 281-288 doi: 10.1016/0264-410x(95)93315-z
Hunt AR, Roehrig JT.In order to define more precisely the protective epitope encoded within the first 25 amino acids (aa) of the E2 glycoprotein of the Trinidad donkey strain of Venezuelan equine encephalomyelitis (VEE) virus, we examined the immunogenicity of smaller peptides within the first 19 aa. pep1-9 and pep3-10 elicited virus-reactive antibody, but failed to protect mice from virus challenge. Additionally, pep3-10 was identified by a competitive binding assay using overlapping peptide octamers as the putative binding site of the antipeptide monoclonal antibody (mAb) 1A2B-10. Since the E2 amino-terminal se...
Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine.
Vaccine    February 1, 1994   Volume 12, Issue 2 142-144 doi: 10.1016/0264-410x(94)90052-3
House JA, Lombard M, Dubourget P, House C, Mebus CA.The immunity induced by two inoculations of a commercial inactivated African horse sickness (AHS) serotype 4 (AHSV-4) vaccine was studied. No adverse reaction was observed in five horses following vaccination. Following challenge-inoculation, no clinical signs attributable to AHS, no viraemia indicating infection, and no anamnestic response was observed in the vaccinated ponies. Two control ponies developed clinical signs typical of AHS, high levels of viraemia, and died 7 and 8 days postchallenge-inoculation. The quality of immunity induced by the two-dose regimen was compared with a one-dose...
WHO/OIE meeting: consultation on newly emerging strains of equine influenza. 18-19 May 1992, Animal Health Trust, Newmarket, Suffolk, UK.
Vaccine    January 1, 1993   Volume 11, Issue 11 1172-1175 doi: 10.1016/0264-410x(93)90092-c
Mumford J, Wood J.No abstract available
Efficacy of equine influenza vaccines for protection against A/Equine/Jilin/89 (H3N8)–a new equine influenza virus.
Vaccine    January 1, 1993   Volume 11, Issue 10 987-993 doi: 10.1016/0264-410x(93)90122-e
Webster RG, Thomas TL.A new H3N8 equine influenza virus [A/Equine/Jilin/1/89 (Eq/Jilin)] appeared in Northeastern China in 1989 and caused high mortality in horses; the available evidence indicates that it has not yet spread outside this region of the world. Serological analysis with postinfection ferret sera in haemagglutination inhibition (HI) tests confirmed that Eq/Jilin is antigenically distinct from H3N8 equine influenza viruses isolated between 1963 and 1991 and also showed that a current equine influenza virus [A/Equine/Alaska/1/91 (H3N8)] had undergone antigenic drift. In the present study we determine if ...
Influenza virus ISCOMs: antibody response in animals.
Vaccine    February 1, 1988   Volume 6, Issue 1 49-53 doi: 10.1016/0264-410x(88)90014-x
Sundquist B, Lövgren K, Morein B.A monovalent experimental ISCOM vaccine has been prepared with the envelope glycoproteins haemagglutinin and neuraminidase of the equine virus strain A/Solvalla/79 (H3N8). In vaccination trials on BALB/c mice the ISCOM vaccine induced more than ten times higher serum antibody titres measured in ELISA than a corresponding experimental micelle vaccine. Similarly, in guinea-pigs the ISCOMs induced about tenfold higher haemagglutination inhibition (HI) and neuraminidase inhibition (NI) titres than a micelle vaccine or a conventional killed influenza whole virus vaccine. Horses vaccinated with a di...